According to the research report titled ‘Global Dyslipidemia Market Analysis, 2020’, available with Market Study Report, global dyslipidemia market is likely to showcase a y-o-y growth rate of 10% between 2020 and 2025.
 

Increasing dominance of dyslipidemia among individuals suffering from diabetes and hypertension in consort with rising obesity rate owing to widespread adoption of sedentary lifestyle are some of the key factors driving the growth of global dyslipidemia market.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2822566/
 

High occurrence of cardiovascular diseases, surging government investments towards development of innovative drugs, and growing demand for diagnostic tests are also aiding towards the market expansion. Also, technological advancements among leading players such as development of non-stain and stain-based therapeutics for cardiovascular and related diseases is favoring global dyslipidemia market scenario.
 

The end-user scope of the market consists of medical laboratories, hospitals and specialty centers and others. According to the report, hospitals accounted for the largest share in global dyslipidemia market in the year 2019, followed by specialty centers and medical laboratories. Growing diagnosis rate of dyslipidemia coupled with rising development of drugs which lower cholesterol levels are favoring the overall market outlook.
 

Regionally, the overall market is classified into North America, Europe, Middle East & Africa, Asia-Pacific, and South America.
 

The prominent companies operating in global dyslipidemia market are Amgen Inc., Novartis AG, Daiichi Sankyo Co. Ltd., Daewoong Pharmaceutical Co. Ltd., Cipla Limited, Abionyx (Cerenis Therapeutics SA), Bristol Myers Squibb, Sanofi S.A., Pfizer Inc., and The Merck Group among others.